Form 4: Director Heinrich Dreismann Receives Myriad Genetics Grant

Director Heinrich Dreismann acquired 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Summary

• Director Heinrich Dreismann was granted 59,701 restricted stock units (RSUs) on June 4, 2026.
• Each RSU represents a contingent right to receive one share of Myriad Genetics common stock.
• The grant increases the director's total beneficial ownership to 231,145 shares.
• The RSUs vest on the earlier of the first anniversary of the grant or the date of the next annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Increased equity stake for a member of the board of directors.

Negatives

• Potential for future dilution of existing shareholders upon the vesting and issuance of the underlying common stock.

Risks

• Market volatility affecting the value of equity compensation.
• Regulatory or operational risks inherent to the genetic testing industry that could impact stock performance.

Future Outlook

The RSUs are expected to vest within one year, contingent upon the passage of time or the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize board members and align their interests with those of the shareholders in the competitive biotechnology and diagnostics sector.

Comparison to Industry Standards

• The grant follows standard industry practices for director compensation in mid-cap healthcare companies.
• Vesting schedules tied to annual meetings are consistent with common corporate governance policies for public companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual vesting and conversion of these units into common stock.

Next Steps

• Vesting of the 59,701 restricted stock units on the earlier of June 4, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation